Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15155876 | 0.77 | SLC9A1 (0.56) | SLC9A1HCAR3GRM2 | |
| SCHEMBL34349 | 0.76 | POLB (0.48) | — | |
| SCHEMBL10552820 | 0.76 | TSHR (0.33) | — | |
| SCHEMBL4006348 | 0.72 | TSHR (0.41) | SLC9A1GRM2 | |
| SCHEMBL5438355 | 0.72 | ALDH1A1 (0.44) | — | |
| SCHEMBL6756160 | 0.70 | — | — | |
| SCHEMBL1823973 | 0.69 | GRM5 (0.34) | — | |
| SCHEMBL34213 | 0.69 | — | — | |
| SCHEMBL3188192 | 0.69 | — | — | |
| SCHEMBL2207685 | 0.68 | RAB9A (0.35) | SLC9A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | claimed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | claimed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | claimed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | claimed |
| US-8071764-B2 | Compounds of reverse turn mimetics and the use thereof (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-06 | — | — | US | claimed |
| EP-2336131-A1 | Hydantoin compounds | Eisai R&D Management Co., Ltd. (JP) | 2011-06-22 | — | — | EP | claimed |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-09 | — | — | US | claimed |
| EP-2212328-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| US-20100113446-A1 | HYDANTOIN COMPOUNDS | GALLAGHER JR BRIAN M | 2010-05-06 | — | — | US | claimed |
| US-7666875-B2 | 1,3,8-triazaspiro(4,5)decane derivatives; antiinflammatory agent for treating rheumatoid arthritis, allergic, multiple sclerosis, autoimmune disease such as inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | claimed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1888583-A2 | HYDANTOIN COMPOUNDS | Eisai Co., Ltd. (JP) | 2008-02-20 | — | — | EP | claimed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| JP-2007513989-A | — | — | 2007-05-31 | — | — | JP | claimed |
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | claimed |
| EP-1742949-A1 | NOVEL-2-(PIPERAZIN-1-YL)-AND-2-([1,4]DIAZEPAN-1-YL)-IMIDAZO[4,5-D]PYRIDAZIN-4-ONE, PRODUCTION AND USE THEREOF AS MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS | Boehringer Ingelheim International GmbH (DE) | 2007-01-17 | — | — | EP | claimed |
| WO-2006128143-A2 | HYDANTOIN COMPOUNDS | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | WO | claimed |
| US-20060270696-A1 | Hydantoin compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| WO-2005058901-A1 | NOVEL 2-(PIPERAZIN-1-YL)- AND 2-([1,4]DIAZEPAN-1-YL)- IMIDAZO[4,5-D]PYRIDAZIN-4-ONE, PRODUCTION AND USE THEREOF AS MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | DPP4, DPP3, DPP7 | SLC9A1 2743/4885KEAP1 1721/4885HCAR3 2985/4885 |
| US-20060270696-A1 | Hydantoin compounds | HNMT, HLA-DRB1, SSB | SLC9A1 101/4885KEAP1 610/4885HCAR3 34/4885 |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | SLC9A1 1872/4885KEAP1 1807/4885HCAR3 2843/4885 |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | MCL1, BID, MYADM | SLC9A1 4576/4885KEAP1 3401/4885HCAR3 2974/4885 |
| US-20100113446-A1 | HYDANTOIN COMPOUNDS | HNMT, HLA-DRB1, SSB | SLC9A1 101/4885KEAP1 610/4885HCAR3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.